Novartis: European Commission approves brolucizumab 6 mg for patients with diabetic macular edema
April 1, 2022 David Hutton, OT Staff Reports Approval is based on year 1 data from the Phase III KESTREL and KITE trials investigating brolucizumab 6 mg versus aflibercept 2 mg…